Scribe Therapeutics Reports 61% Decline in Collaboration Revenue for Q2 2026

Scribe Therapeutics, Inc. reported a significant decline in financial performance for the second quarter of 2026, with collaboration revenue dropping to $1.9 million from $4.9 million in the same period last year, marking a 61% decrease. For the six months ended June 30, 2026, total collaboration revenue was $4.2 million, down 81% from $22.0 million in the prior year. The decrease was primarily attributed to reduced reimbursable research and development activities with Eli Lilly and the absence of revenue from Sanofi, which had contributed $0.5 million in the previous year. The company incurred a net loss of $6.5 million for the quarter, a 35% improvement compared to a loss of $9.9 million in Q2 2025.

Operating expenses also saw a notable reduction, totaling $11.3 million for the second quarter, down 32% from $16.5 million in the prior year. Research and development expenses decreased by 36% to $8.8 million, driven by lower employee-related costs and reduced external research expenses. General and administrative expenses also fell by 6% to $2.5 million. The company’s accumulated deficit reached $181.5 million as of June 30, 2026, reflecting ongoing investments in research and development without generating product revenue.

In terms of strategic developments, Scribe Therapeutics completed its initial public offering (IPO) on July 27, 2026, raising approximately $148 million in gross proceeds. This was complemented by a concurrent private placement with Sanofi, generating an additional $7.5 million. The company believes that the net proceeds from these offerings, along with existing cash and investments totaling $43 million, will be sufficient to fund operations into the first half of 2029. The IPO and private placement alleviated previous concerns regarding the company’s ability to continue as a going concern.

Operationally, Scribe Therapeutics is advancing its lead product candidate, STX-1150, through a Phase 1 clinical trial aimed at reducing low-density lipoprotein cholesterol (LDL-C). The company also received approximately $25.7 million in grant funding from the California Institute for Regenerative Medicine to support the development of its STX-1200 and STX-1400 programs. As of June 30, 2026, the company had 2,485,234 shares of common stock outstanding, reflecting a reverse stock split that took effect on July 17, 2026.

Looking ahead, Scribe Therapeutics anticipates continued investment in its clinical and preclinical programs, with expectations of increased operating expenses as it advances its product candidates. The company remains focused on leveraging its proprietary CRISPR technologies to address unmet medical needs in cardiometabolic diseases, while also exploring strategic collaborations to enhance its development capabilities and financial position.